Patents by Inventor Srinivas Gullapalli

Srinivas Gullapalli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical composition comprising a TRPA1 antagonist and an analgesic agent
    Patent number: 9532988
    Abstract: The present patent application relates to a pharmaceutical composition comprising a TRPA1 antagonist and an analgesic agent. Particularly, the present patent application provides a pharmaceutical composition comprising a thienopyrimidinedione compound as a TRPA1 antagonist and an analgesic agent; and use of such composition for treating pain in a subject.
    Type: Grant
    Filed: October 14, 2014
    Date of Patent: January 3, 2017
    Assignee: GLENMARK PHARMACEUTICALS S.A.
    Inventors: Srinivas Gullapalli, Praveen Kumar Gupta, Maulik Nitinkumar Gandhi
  • Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
    Patent number: 8420689
    Abstract: The present invention relates to novel cannabinoid receptor modulators, in particular cannabinoid 1 (CB1) or cannabinoid 2 (CB2) receptor modulators, and uses thereof for treating diseases, conditions and/or disorders modulated by a cannabinoid receptor.
    Type: Grant
    Filed: January 14, 2011
    Date of Patent: April 16, 2013
    Assignee: Glenmark Pharmaceuticals S.A.
    Inventors: Meyyappan Muthuppalaniappan, Gopalan Balasubramanian, Srinivas Gullapalli, Neelima Khairatkar Joshi, Shridhar Narayanan
  • Quinazolinedione derivatives as TRPA1 modulators
    Patent number: 7951814
    Abstract: The present invention provides Quinazolinedione derivatives as TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1.
    Type: Grant
    Filed: June 16, 2009
    Date of Patent: May 31, 2011
    Assignee: Glenmark Pharmaceuticals, S.A.
    Inventors: Meyyappan Muthuppalniappan, Abraham Thomas, Sukeerthi Kumar, Sanjay Margal, Neelima Khairatkar-Joshi, Indranil Mukhopadhyay, Srinivas Gullapalli
  • Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
    Patent number: 7923465
    Abstract: The present invention relates to novel cannabinoid receptor modulators, in particular cannabinoid 1 (CB1) or cannabinoid 2 (CB2) receptor modulators, and uses thereof for treating diseases, conditions and/or disorders modulated by a cannabinoid receptor (such as pain, neurodegenerative disorders, eating disorders, weight loss or control, and obesity).
    Type: Grant
    Filed: June 1, 2006
    Date of Patent: April 12, 2011
    Assignee: Glenmark Pharmaceuticals S.A.
    Inventors: Meyyappan Muthuppalaniappan, Gopalan Balasubramanian, Srinivas Gullapalli, Neelima Khairatkar Joshi, Shridhar Narayanan
  • QUINAZOLINEDIONE DERIVATIVES AS TRPA1 MODULATORS
    Publication number: 20090325987
    Abstract: The present invention provides Quinazolinedione derivatives as TRPA (Transient Receptor Potential subfamily A) modulators. In particular, compounds described herein are useful for treating or preventing diseases, conditions and/or disorders modulated by TRPA1 (Transient Receptor Potential subfamily A, member 1). Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders modulated by TRPA1.
    Type: Application
    Filed: June 16, 2009
    Publication date: December 31, 2009
    Applicant: Glenmark Pharmaceuticals, S.A.
    Inventors: Meyyappan Muthuppalniappan, Abraham Thomas, Sukeerthi Kumar, Sanjay Margal, Neelima Khairatkar-Joshi, Indranil Mukhopadhyay, Srinivas Gullapalli
  • Novel Cannabinoid Receptor Ligands, Pharmaceutical Compositions Containing Them, and Process For Their Preparation
    Publication number: 20080234259
    Abstract: The present invention relates to novel cannabinoid receptor modulators, in particular cannabinoid 1 (CB1) or cannabinoid 2 (CB2) receptor modulators, and uses thereof for treating diseases, conditions and/or disorders modulated by a cannabinoid receptor (such as pain, neurodegenative disorders, eating disorders, weight loss or control, and obesity).
    Type: Application
    Filed: June 1, 2006
    Publication date: September 25, 2008
    Applicant: Glenmark Pharmaceuticals S.A.
    Inventors: Meyyappan Muthuppalaniappan, Gopalan Balasubramanian, Srinivas Gullapalli, Neelima Khairatkar Joshi, Shridhar Narayanan
  • NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESSES FOR THEIR PREPARATION
    Publication number: 20080200501
    Abstract: The present invention relates to novel cannabinoid receptor modulators, in particular cannabinoid 1 (CB1) or cannabinoid 2 (CB2) receptor modulators, and uses thereof for treating diseases, conditions and/or disorders modulated by a cannabinoid receptor (such as pain, neurodegenative disorders, eating disorders, weight loss or control, and obesity).
    Type: Application
    Filed: November 2, 2007
    Publication date: August 21, 2008
    Applicant: Glenmark Pharmaceuticals S.A.
    Inventors: Meyyappan Muthuppalaniappan, Kumar Sukeerthi, Gopalan Balasubramanian, Srinivas Gullapalli, Neelima Khairatkar Joshi, Shridhar Narayanan, Pallavi V. Kamik